BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32656925)

  • 21. Identifying patients with NTRK fusion cancer.
    Solomon JP; Benayed R; Hechtman JF; Ladanyi M
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
    Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
    Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
    Amatu A; Sartore-Bianchi A; Bencardino K; Pizzutilo EG; Tosi F; Siena S
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
    Bebb DG; Banerji S; Blais N; Desmeules P; Gill S; Grin A; Feilotter H; Hansen AR; Hyrcza M; Krzyzanowska M; Melosky B; Noujaim J; Purgina B; Ruether D; Simmons CE; Soulieres D; Torlakovic EE; Tsao MS
    Curr Oncol; 2021 Jan; 28(1):523-548. PubMed ID: 33467570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
    Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
    J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
    Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
    Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW; Hong DS
    Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients.
    Perreault S; Chami R; Deyell RJ; El Demellawy D; Ellezam B; Jabado N; Morgenstern DA; Narendran A; Sorensen PHB; Wasserman JD; Yip S
    Curr Oncol; 2021 Jan; 28(1):346-366. PubMed ID: 33435412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes.
    Chetty R
    J Clin Pathol; 2019 Mar; 72(3):187-190. PubMed ID: 30636697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ; Zehir A; Sireci AN; Aisner DL
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
    Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
    Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase separation underlies signaling activation of oncogenic NTRK fusions.
    Zhu T; Xie J; He H; Li H; Tang X; Wang S; Li Z; Tian Y; Li L; Zhu J; Zhu G
    Proc Natl Acad Sci U S A; 2023 Oct; 120(42):e2219589120. PubMed ID: 37812694
    [No Abstract]   [Full Text] [Related]  

  • 34. NTRK fusions and Trk proteins: what are they and how to test for them.
    Weiss LM; Funari VA
    Hum Pathol; 2021 Jun; 112():59-69. PubMed ID: 33794242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project.
    Bridgewater J; Jiao X; Parimi M; Flach C; Stratford J; Kamburov A; Schmitz AA; Zong J; Reeves JA; Keating K; Bruno A; Fellous M; Pereira MB; Bazhenova L
    Cancer Treat Res Commun; 2022; 33():100623. PubMed ID: 36041373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
    Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
    Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans.
    Zhou KI; Vashistha V; Guo A; Ahmed S; Kelley MJ
    JCO Precis Oncol; 2023 Mar; 7():e2200692. PubMed ID: 36926986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NTRK fusions in lung cancer: From biology to therapy.
    Harada G; Santini FC; Wilhelm C; Drilon A
    Lung Cancer; 2021 Nov; 161():108-113. PubMed ID: 34563714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.
    Xu C; Si L; Wang W; Li Z; Song Z; Wang Q; Liu A; Yu J; Fang W; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Cai X; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Lin R; Liu W; Rao C; Lv D; Yu Z; Lei L; Li X; Tang C; Zhou C; Zhang J; Xue J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Hu X; Zhou J; Zhu Z; Li Y; Qiu H; Xia F; Lu Y; Chen X; Ge R; Dai E; Han Y; Pan W; Luo J; Jia H; Dong X; Pang F; Wang K; Wang L; Zhu Y; Xie Y; Lin X; Cai J; Wei J; Lan F; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Wei Q; Kang J; Zhang J; Zhang C; Yu G; Ou J; Shi L; Li Z; Liu Z; Liu J; Yang N; Wu L; Wang H; Jin G; Yang L; Wang G; Fang M; Fang Y; Li Y; Wang X; Zhang Y; Ma S; Wang B; Zhang X; Song Y; Lu Y
    Thorac Cancer; 2022 Nov; 13(21):3084-3097. PubMed ID: 36127731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer.
    Schraa SJ; Stelloo E; Laclé MM; Swennenhuis JF; Brosens LAA; Fijneman RJA; Feitsma H; Koopman M; de Leng WW; Vink GR; Bol GM
    Virchows Arch; 2023 Jun; 482(6):983-992. PubMed ID: 37067589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.